Fierce Biotech June 18, 2024
Boston Scientific is en route to expand its vascular offerings with a $1.26 billion deal to acquire Silk Road Medical and its approach to reducing the risk of stroke via carotid artery procedures.
Silk Road is known as the developer of TCAR, for transcarotid artery revascularization. In patients that need a stent to help clear a path through a plaque-filled vessel, the company’s Enroute hardware temporarily reverses the flow of blood, to redirect any potentially dangerous loose clots away from the brain.
“The TCAR platform developed by Silk Road Medical is a notable advancement in the field of vascular medicine, which has revolutionized stroke prevention and the treatment of carotid artery disease,” Boston Scientific’s president of vascular peripheral interventions, Cat...
Today's Sponsors
Today's Sponsor